BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D. Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clin Pharmacokinet 2016;55:1381-94. [PMID: 27312193 DOI: 10.1007/s40262-016-0406-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Boisteau E, François E, Aparicio T, Le Malicot K, Boulahssass R, Lecomte T, Laurent-Puig P, Guiu B, Paillaud E, Galais MP, Lopez-Trabada Ataz D, Tougeron D, Dourthe LM, Guimbaud R, Samalin E, Moreau M, Louvet C, Lepage C, Lièvre A. SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer. Dig Liver Dis 2022:S1590-8658(22)00206-7. [PMID: 35351371 DOI: 10.1016/j.dld.2022.03.001] [Reference Citation Analysis]
2 Benitez JC, Geraud A, Texier M, Massard C, Paci A, Soria JC, Besse B. Late phase 1 studies: concepts and outcomes. Lancet Oncol 2021;22:e446-55. [PMID: 34592194 DOI: 10.1016/S1470-2045(21)00467-8] [Reference Citation Analysis]
3 Marin C, Khoudour N, Millet A, Lebert D, Bros P, Thomas F, Ternant D, Lacarelle B, Guitton J, Ciccolini J, Blanchet B. Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. Pharmaceuticals (Basel) 2021;14:796. [PMID: 34451893 DOI: 10.3390/ph14080796] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Petitcollin A, Azzopardi N, Pierga JY, Ternant D, Navarro-Teulon I, Desvignes C, Mouret-Reynier MA, Coudert B, Paintaud G. Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early-stage breast cancer. Eur J Clin Pharmacol 2021. [PMID: 34245336 DOI: 10.1007/s00228-021-03179-w] [Reference Citation Analysis]
5 Peña-Cabia S, Royuela Vicente A, Ramos Díaz R, Gutiérrez Nicolás F, Peñalver Vera Á, Siso García I, Hitt Sabag R, García Lacalle C, Peña-Cabia A, Iglesias-Peinado I, García Díaz B, López-Martín A. Assessment of exposure-response relationship for bevacizumab in patients with metastatic colorectal cancer. Biomed Pharmacother 2021;141:111827. [PMID: 34153845 DOI: 10.1016/j.biopha.2021.111827] [Reference Citation Analysis]
6 Chung C. Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation. J Oncol Pharm Pract 2021;:10781552211005525. [PMID: 33832365 DOI: 10.1177/10781552211005525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Chatelut E, Hendrikx JJMA, Martin J, Ciccolini J, Moes DJAR. Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. Pharmacol Res Perspect 2021;9:e00757. [PMID: 33745217 DOI: 10.1002/prp2.757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Patel DD, Bussel JB. Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention. J Allergy Clin Immunol 2020;146:467-78. [PMID: 32896307 DOI: 10.1016/j.jaci.2020.07.015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
9 Sabatier R, Pierga JY, Curé H, Abulnaja R, Lambaudie E, Bidard FC, Extra JM, Sfumato P, Gonçalves A. Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. Cancers (Basel) 2021;13:E140. [PMID: 33466225 DOI: 10.3390/cancers13010140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Le Louedec F, Chatelut E. Correlation Between Bevacizumab Exposure and Survival Does Not Necessarily Imply Causality. Oncologist 2020;25:e2022. [PMID: 33044752 DOI: 10.1002/onco.13564] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Centanni M, Moes DJAR, Trocóniz IF, Ciccolini J, van Hasselt JGC. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. Clin Pharmacokinet 2019;58:835-57. [PMID: 30815848 DOI: 10.1007/s40262-019-00748-2] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 38.5] [Reference Citation Analysis]
12 Papachristos A, Sivolapenko GB. Pharmacogenomics, Pharmacokinetics and Circulating Proteins as Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review. J Pers Med 2020;10:E79. [PMID: 32759686 DOI: 10.3390/jpm10030079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
13 Ferrer F, Fanciullino R, Milano G, Ciccolini J. Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations. Clin Pharmacol Ther 2020;108:458-70. [PMID: 32557660 DOI: 10.1002/cpt.1954] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
14 Papachristos A, Karatza E, Kalofonos H, Sivolapenko G. Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer. Int J Mol Sci 2020;21:E3753. [PMID: 32466535 DOI: 10.3390/ijms21113753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
15 Papachristos A, Kemos P, Kalofonos H, Sivolapenko G. Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer. Oncologist 2020;25:853-8. [PMID: 32272489 DOI: 10.1634/theoncologist.2019-0835] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
16 Novo I, Campos B, Pinto-ribeiro F, Martins SF. Coadjuvant Anti-VEGF A Therapy Improves Survival in Patients with Colorectal Cancer with Liver Metastasis: A Systematic Review. GastrointestDisord 2020;2:71-85. [DOI: 10.3390/gidisord2020007] [Reference Citation Analysis]
17 Ternant D, Azzopardi N, Raoul W, Bejan-Angoulvant T, Paintaud G. Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. Clin Pharmacokinet 2019;58:169-87. [PMID: 29802542 DOI: 10.1007/s40262-018-0680-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
18 Bensalem A, Ternant D. Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications. Clin Pharmacokinet 2020;59:857-74. [DOI: 10.1007/s40262-020-00874-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
19 Paci A, Desnoyer A, Delahousse J, Blondel L, Maritaz C, Chaput N, Mir O, Broutin S. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers. European Journal of Cancer 2020;128:107-18. [DOI: 10.1016/j.ejca.2020.01.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
20 Dolly A, Lecomte T, Bouché O, Borg C, Terrebonne E, Douillard JY, Chautard R, Raoul W, Ternant D, Leger J, Bleuzen A, Dumas JF, Servais S, Baracos VE. Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancer. Clin Nutr 2020;39:3319-30. [PMID: 32164981 DOI: 10.1016/j.clnu.2020.02.017] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Ternant D, Chhun S. [Pharmacokinetic variability of therapeutic antibodies]. Med Sci (Paris) 2019;35:1130-6. [PMID: 31903927 DOI: 10.1051/medsci/2019210] [Reference Citation Analysis]
22 Thomas VA, Balthasar JP. Understanding Inter-Individual Variability in Monoclonal Antibody Disposition. Antibodies (Basel) 2019;8:E56. [PMID: 31817205 DOI: 10.3390/antib8040056] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
23 Chatelut E, Le Louedec F, Milano G. Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology. Clin Pharmacokinet 2020;59:287-96. [PMID: 31701469 DOI: 10.1007/s40262-019-00837-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
24 Millet A, Lebert D, Picard G, You B, Ceruse P, Guitton J. Determination of Cetuximab in Plasma by Liquid Chromatography-High-Resolution Mass Spectrometry Orbitrap With a Stable Labeled 13C,15N-Cetuximab Internal Standard. Ther Drug Monit 2019;41:467-75. [PMID: 31306393 DOI: 10.1097/FTD.0000000000000613] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
25 Gal J, Milano G, Ferrero JM, Saâda-Bouzid E, Viotti J, Chabaud S, Gougis P, Le Tourneau C, Schiappa R, Paquet A, Chamorey E. Optimizing drug development in oncology by clinical trial simulation: Why and how? Brief Bioinform 2018;19:1203-17. [PMID: 28575140 DOI: 10.1093/bib/bbx055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
26 Morotti M, Dass PH, Harris AL, Lord S. Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients. Eur J Drug Metab Pharmacokinet 2018;43:137-53. [PMID: 29019020 DOI: 10.1007/s13318-017-0442-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
27 Vialaret J, Broutin S, Pugnier C, Santelé S, Jaffuel A, Barnes A, Tiers L, Pelletier L, Lehmann S, Paci A, Hirtz C. What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum? Bioanalysis 2018;10:723-35. [DOI: 10.4155/bio-2018-0027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
28 Ibrahim S, Raoul W, Lecomte T, Paintaud G, Ternant D. Pharmacokinetics partly explains the relationship between carcinoembryonic antigen level and survival of colorectal cancer patients treated with ramucirumab. European Journal of Cancer 2018;92:119-20. [DOI: 10.1016/j.ejca.2017.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Gougis P, Wassermann J, Spano JP, Keynan N, Funck-Brentano C, Salem JE. Clinical pharmacology of anti-angiogenic drugs in oncology. Crit Rev Oncol Hematol 2017;119:75-93. [PMID: 28916378 DOI: 10.1016/j.critrevonc.2017.08.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
30 Paintaud G, Passot C, Ternant D, Bertolotto A, Bejan-angoulvant T, Pascual-salcedo D, Mulleman D. Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases. Therapeutic Drug Monitoring 2017;39:339-43. [DOI: 10.1097/ftd.0000000000000410] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 2.4] [Reference Citation Analysis]
31 Puszkiel A, Noé G, Boudou-rouquette P, Cossec CL, Arrondeau J, Giraud J, Thomas-schoemann A, Alexandre J, Vidal M, Goldwasser F, Blanchet B. Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients. Journal of Pharmaceutical and Biomedical Analysis 2017;139:30-6. [DOI: 10.1016/j.jpba.2017.02.041] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
32 Lereclus E, Tout M, Girault A, Baroukh N, Caulet M, Borg C, Bouché O, Ternant D, Paintaud G, Lecomte T, Raoul W. A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen. BMC Cancer 2017;17:220. [PMID: 28347290 DOI: 10.1186/s12885-017-3210-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]